I-BET151 (GSK1210151A)

Catalog No.S2780

I-BET151 (GSK1210151A) Chemical Structure

Molecular Weight(MW): 415.44

I-BET151 (GSK1210151A) is a novel selective BET inhibitor for BRD2, BRD3 and BRD4 with IC50 of 0.5 μM, 0.25 μM, and 0.79 μM in cell-free assays, respectively.

Size Price Stock Quantity  
USD 170 In stock
USD 270 In stock
USD 870 In stock
Bulk Discount

Free Overnight Delivery on orders over $ 500
Next day delivery by 10:00 a.m. Order now.

2 Customer Reviews

  • OVTOKO and OVCA420 cells were treated with DMSO, JQ1 (1 μM) or I-BET151 (1 μM). Cell lysates were immunoblotted with indicated antibodies.

    Theranostics, 2016, 6(2):219-30.. I-BET151 (GSK1210151A) purchased from Selleck.

    B. Western blot analysis of pERK and ERK in cells treated with JQ1 or I-BET151.

    Oncotarget, 2016, 7(3):2545-54. I-BET151 (GSK1210151A) purchased from Selleck.

Purity & Quality Control

Choose Selective Epigenetic Reader Domain Inhibitors

Biological Activity

Description I-BET151 (GSK1210151A) is a novel selective BET inhibitor for BRD2, BRD3 and BRD4 with IC50 of 0.5 μM, 0.25 μM, and 0.79 μM in cell-free assays, respectively.
Features Optimized to retain excellent BET target potency and selectivity while enhancing the in vivo pharmacokinetics and terminal half-life to enable prolonged in vivo studies.
Targets
BRD3 [1]
(Cell-free assay)
BRD2 [1]
(Cell-free assay)
BRD4 [1]
(Cell-free assay)
0.25 μM 0.5 μM 0.79 μM
In vitro

I-BET151 exhibits potent selectivity over an extensive range of diverse protein types such as COX-2, P450, Aurora B, GSK3β, PI3K-γ, GPCR, ion channels, and transporters. Similar to I-BET762 (GSK525762A), I-BET151 displays potent binding affinity to BRD2, BRD3 and BRD4 with KD of 0.02-0.1 μM, and significantly inhibits lipopolysaccharide-stimulated IL-6 cytokine production in human peripheral blood mononuclear cells (PBMC) and whole blood (WB) as well as rat WB with IC50 of 0.16 μM, 1.26 μM, and 1.26 μM, respectively. I-BET151 (0.5 or 5 μM) inhibits the binding of BETs (BRD2, BRD3, BRD4, and BRD9) but not the binding of 23 other bromodomain proteins in HL60 nuclear extract to acetylated histone peptides. I-BET151 has potent efficacy against cell lines harboring different MLL-fusions such as MV4;11, RS4;11, MOLM13, and NOMO1 cells with IC50 of 15-192 nM. Consistently, I-BET151 completely ablates the colony-forming potential of MLL-fusion-driven leukaemias (MOLM13) but not leukaemias driven by tyrosine kinase activation (K562). I-BET151 also displays potent efficacy in both liquid culture and clonogenic assays using primary murine progenitors transformed with either MLL-ENL or MLL-AF9. I-BET151 treatment significantly induces apoptosis and prominent G0/G1 arrest in MLL-fusion cell lines driven by distinct MLL fusions (MOLM13 and MV4;11 containing MLL-AF9 and MLL-AF4, respectively) but not the K562 cells, probably due to the inhibition of transcription of BCL2, C-MYC and CDK6 by blocking the recruitment of BRD3/4, PAFc and SEC components into transcriptional start site (TSS). [1]

Cell Data
Cell Lines Assay Type Concentration Incubation Time Formulation Activity Description PMID
MV4;11 NFfrWXJkgXSxdH;4bYNqfHliYYPzZZk> M{f2Rp4yODBizszN Mo[5SG1UVw>? NInpTJdKSzVyPUK2JI5O M3fDPFIyQTZ2M{Sw
RS4;11 NF[1codkgXSxdH;4bYNqfHliYYPzZZk> NEfMOpJ,OTByIN88US=> NIjx[VJFVVOR NELsV2RKSzVyPUG5NkBvVQ>? NVTle21tOjF7NkSzOFA>
MOLM13 NEDGT3VkgXSxdH;4bYNqfHliYYPzZZk> M1XZcZ4yODBizszN MoP3SG1UVw>? NEi1VI1KSzVyPUGyNEBvVQ>? MVGyNVk3PDN2MB?=
NOMO1 M3rmZ4N6fG:2b4jpZ4l1gSCjc4PhfS=> MXT+NVAxKM7:TR?= MXrEUXNQ MlGxTWM2OD1zNTDuUS=> M{fVW|IyQTZ2M{Sw
HEL M37rcYN6fG:2b4jpZ4l1gSCjc4PhfS=> MX3+NVAxKM7:TR?= MorvSG1UVw>? NVvWOY46UUN3ME2xJO69VQ>? MWGyNVk3PDN2MB?=
K562 M37rXoN6fG:2b4jpZ4l1gSCjc4PhfS=> MmX4glExOCEQvF2= M4XZcGROW09? M4HY[2lEPTB-MUCwJO69VQ>? MUmyNVk3PDN2MB?=
MEG01 M{TMXYN6fG:2b4jpZ4l1gSCjc4PhfS=> MkfwglExOCEQvF2= NVG1R4E6TE2VTx?= MWnJR|UxRTJ3IN88US=> NFXJW3kzOTl4NEO0NC=>
HL60 MonsZ5l1d3SxeHnjbZR6KGG|c3H5 NFrpVIF,OTByIN88US=> MkKwSG1UVw>? MnvYTWM2OD16OUCgcm0> MmXtNlE6PjR|NEC=
MV4;11 MoPIRZBweHSxc3nzJIF{e2G7 MlLmglExOCEQvF2= M2jQWGROW09? NW\BPZhWcW6mdXPld{BieG:ydH;zbZM> NETJNXozOTl4NEO0NC=>
MOLM13 MkTlRZBweHSxc3nzJIF{e2G7 MVz+NVAxKM7:TR?= Mk\iSG1UVw>? Ml3MbY5lfWOnczDhdI9xfG:|aYO= M2\oOFIyQTZ2M{Sw
MV4;11 NIC3eFZHfW6ldHnvckBie3OjeR?= NWPmOWxvTE2VTx?= MYLk[YNz\WG|ZYOgeIhmKHKnY4L1bZRu\W62IH;mJGJTTDNxNDDhcoQhcW2yYXny[YQhemWlcoXpeI1mdnRib3[gR2RMQSCjbnSgVGFHOSC2bzD0bIUhfHKjboPjdolxfGmxbnHsJJN1[XK2IIPpeIU> MX:yNVk3PDN2MB?=
PBMC M2CxN2Z2dmO2aX;uJIF{e2G7 NVHVUlc2TE2VTx?= M135ZolvcGmkaYTzJGlNNTZid3n0bEBxUUN3MDDv[kA3Njd? MmTTNlI1OzdzMUW=
A2 NYfYTpNnTnWwY4Tpc44h[XO|YYm= M3Tmep4yOCEQvF2= NEm2[49FVVOR NXH1[o9PemWjY4TpeoF1\XNibHH0[Y51KEiLVj2x NWTweHhZOjN{NUWyNVg>
A72 NGTCZYtHfW6ldHnvckBie3OjeR?= MV;+NVAh|ryP NV7JPVdsTE2VTx?= MofHdoVi[3SrdnH0[ZMhdGG2ZX70JGhKXi1z NHfQSmozOzJ3NUKxPC=>
BC1 Mn\1S5Jwf3SqIHnubIljcXSxcomgZZN{[Xl? MVP+NUDPxE1? MnzwSG1UVw>? MkXyTWM2OD1{MkCgcm0> M{HLdVI{Pzl{NES4
BC3 NWfzems3T3Kxd4ToJIlvcGmkaYTvdpkh[XO|YYm= NF64OGt,OSEQvF2= MVjEUXNQ NWrBeHZWUUN3ME20OlAhdk1? Mk\WNlM4QTJ2NEi=
BCBL1 NEeyd2NIem:5dHigbY5pcWKrdH;yfUBie3OjeR?= NH7TR|V,OSEQvF2= Mk\DSG1UVw>? MWLJR|UxRTN|MDDuUS=> NHOwSZMzOzd7MkS0PC=>
BJAB NUDxU4h1T3Kxd4ToJIlvcGmkaYTvdpkh[XO|YYm= NWfCXIJOhjFizszN MWDEUXNQ NWfNVXY2UUN3ME25O|Ahdk1? NYK3UldPOjN5OUK0OFg>
Namalwa NGr0eYJIem:5dHigbY5pcWKrdH;yfUBie3OjeR?= NIrGeYZ,OSEQvF2= NViyWGlVTE2VTx?= MmrVTWM2OD17N{Cgcm0> MV2yN|c6OjR2OB?=
Jurkat NHLuSItIem:5dHigbY5pcWKrdH;yfUBie3OjeR?= MnTRglEh|ryP MnTMSG1UVw>? MUTJR|UxRTF{MkCgcm0> MoPGNlM4QTJ2NEi=
MM1S NVLLbWJ1T3Kxd4ToJIlvcGmkaYTvdpkh[XO|YYm= NHrzOJJ,OSEQvF2= Ml\GSG1UVw>? MmPBTWM2OD15NkCgcm0> NILi[pIzOzd7MkS0PC=>
U266 Mk\3S5Jwf3SqIHnubIljcXSxcomgZZN{[Xl? MW\+NUDPxE1? NInSNYRFVVOR MXzJR|UxRTl3MDDuUS=> MWGyN|c6OjR2OB?=
UM-PEL-1 NI\kdY9Iem:5dHigbY5pcWKrdH;yfUBie3OjeR?= NXnCcHl1hjFizszN NHn4ZllFVVOR MWXJR|UxRTJzMDDuUS=> MlHoNlM4QTJ2NEi=
UM-PEL-3 M3L0UGdzd3e2aDDpcohq[mm2b4L5JIF{e2G7 MkToglEh|ryP NF;aSXFFVVOR NXLEdnJ4UUN3ME2xPFAhdk1? NXfr[nNJOjN5OUK0OFg>
BC1 M4nzfmZ2dmO2aX;uJIF{e2G7 MYW1NFAhdk1? M1HTZWROW09? MVTpcoR2[2W|IHPlcIwu[3mlbHWgZZJz\XO2 M1PzTVI{Pzl{NES4
BC3 NWK0PYNDTnWwY4Tpc44h[XO|YYm= MXW1NFAhdk1? M17FbWROW09? NGWye3pqdmS3Y3XzJINmdGxvY4njcIUh[XK{ZYP0 MknzNlM4QTJ2NEi=
BC1 NVv2SGRITnWwY4Tpc44h[XO|YYm= NHT0Z405ODBibl2= M4\xTmROW09? NGL4bFlz\WS3Y3XzJIMuVXmlIIDyc5RmcW5ibHX2[Yx{ MonvNlM4QTJ2NEi=
BC3 NEOzUXlHfW6ldHnvckBie3OjeR?= M13nRlgxOCCwTR?= NFfLPZhFVVOR NETtR4xz\WS3Y3XzJIMuVXmlIIDyc5RmcW5ibHX2[Yx{ MWmyN|c6OjR2OB?=
H929 MmfISpVv[3Srb36gZZN{[Xl? MoPmglEh|ryP MW\EUXNQ MWrpcoR2[2W|IHPlcIwh[3mlbHWgZZJz\XO2 MkL4NlQ{OzV2OUm=
KMS12PE MX\GeY5kfGmxbjDhd5NigQ>? MoLaglEh|ryP NEfTfFRFVVOR MmHJbY5lfWOnczDj[YxtKGO7Y3zlJIFzemW|dB?= NG\JO4ozPDN|NUS5PS=>
KMS12BM M4XUPGZ2dmO2aX;uJIF{e2G7 M4G5NJ4yKM7:TR?= M1fX[WROW09? M1mwVYlv\HWlZYOgZ4VtdCCleXPs[UBienKnc4S= MXyyOFM{PTR7OR?=
KMS18 NVj1e5dTTnWwY4Tpc44h[XO|YYm= Ml3BglEh|ryP M3HjXmROW09? NEHtZ4NqdmS3Y3XzJINmdGxiY4njcIUh[XK{ZYP0 Mk\3NlQ{OzV2OUm=
KMS11 MYnGeY5kfGmxbjDhd5NigQ>? M2P4N54yKM7:TR?= MoPGSG1UVw>? MkDNbY5lfWOnczDj[YxtKGO7Y3zlJIFzemW|dB?= NYflVlB1OjR|M{W0PVk>
RPMI8226 MY\GeY5kfGmxbjDhd5NigQ>? MVn+NUDPxE1? M2S4OmROW09? NY[4OG1QcW6mdXPld{Bk\WyuIHP5Z4xmKGG{cnXzeC=> MorKNlQ{OzV2OUm=
H929 M1nUfmFxd3C2b4Ppd{Bie3OjeR?= MW\+NUDPxE1? NFrnUlhFVVOR M3LPXolv\HWlZYOgZ4VtdCCjcH;weI9{cXN? MXSyOFM{PTR7OR?=
KMS12PE NVXRTXZlSXCxcITvd4l{KGG|c3H5 MVP+NUDPxE1? M2DpZ2ROW09? NXvvXHV5cW6mdXPld{Bk\WyuIHHwc5B1d3Orcx?= NUPofFhOOjR|M{W0PVk>
KMS12BM Mnr5RZBweHSxc3nzJIF{e2G7 Mof2glEh|ryP NEHzTIFFVVOR M2\qPIlv\HWlZYOgZ4VtdCCjcH;weI9{cXN? NGTXUmwzPDN|NUS5PS=>
KMS18 MYjBdI9xfG:|aYOgZZN{[Xl? MmTsglEh|ryP M1PqbmROW09? NUHGbZJscW6mdXPld{Bk\WyuIHHwc5B1d3Orcx?= MoHPNlQ{OzV2OUm=
KMS11 MXnBdI9xfG:|aYOgZZN{[Xl? Mnu1glEh|ryP MnfsSG1UVw>? MUTpcoR2[2W|IHPlcIwh[XCxcITvd4l{ MVuyOFM{PTR7OR?=
RPMI8226 M3rTXmFxd3C2b4Ppd{Bie3OjeR?= M3rBSJ4yKM7:TR?= MoG5SG1UVw>? NGnRWJdqdmS3Y3XzJINmdGxiYYDvdJRwe2m| NF:xdoQzPDN|NUS5PS=>
U87MG Mk\zSpVv[3Srb36gZZN{[Xl? M2q0PZ4yOCEQvF2= MVjEUXNQ NGP4NYVz\WS3Y3XzJHU5P02JIHPlcIx2dGG{IFHUVEB4cXSqIFnDOVAhd2ZiMT6wOUDPxE1? MXSyOFQ6PjN6MR?=
A172 NXTPUFZYTnWwY4Tpc44h[XO|YYm= NXOz[GtkhjFyIN88US=> MXjEUXNQ NFjIem1z\WS3Y3XzJINmdGy3bHHyJGFVWCC5aYToJGlEPTBib3[gNU4zQCEQvF2= MXyyOFQ6PjN6MR?=
SW1783 NYfmdIxkTnWwY4Tpc44h[XO|YYm= M2PXXZ4yOCEQvF2= MkH2SG1UVw>? MnzDdoVlfWOnczDj[YxtfWyjcjDBWHAhf2m2aDDJR|UxKG:oIEKuOlgh|ryP M1zw[|I1PDl4M{ix
U87MG MXXGeY5kfGmxbjDhd5NigQ>? NWfTZopihjFyIN88US=> MlTwSG1UVw>? M{X0V4lv[3KnYYPld{Bxem:yb4L0bY9vKG:oIHPlcIx{KGmwIITo[UBIOS:VIITyZY5{cXSrb36= MlO4NlQ1QTZ|OEG=
RAW267.4 NVzWWXIxTnWwY4Tpc44h[XO|YYm= M3XjTVEh|ryP NWK2WnRzTE2VTx?= MWPy[YR2[2W|IFnMMVYheHKxZIXjeIlwdiCrbnT1Z4VlKGK7IFzQVy=> MmDZNlQ5PTlyMEi=
RAW267.4 NXHTeXQ{TnWwY4Tpc44h[XO|YYm= MmXvNUDPxE1? MVnEUXNQ MYjy[YR2[2W|IITo[UBie3OxY3nheIlwdiCkZYT3[YVvKEKURESgZY5lKGGlZYT5cIF1\WRicE[1 NYfvVGpGOjR6NUmwNFg>
Me007 M1TEWmdzd3e2aDDpcohq[mm2b4L5JIF{e2G7 M3Lwep4yODBizszN NVrZT45jTE2VTx?= MVTpcohq[mm2czD0bIUh\3Kxd4To NVLwXpM{OjR7ME[xN|c>
SK-Mel-28 NUnucJFNT3Kxd4ToJIlvcGmkaYTvdpkh[XO|YYm= NVXDfVAyhjFyMDFOwG0> NIroNnpFVVOR NXnTdZBycW6qaXLpeJMhfGinIHfyc5d1cA>? NF2wbIMzPDlyNkGzOy=>
Mel-RMU Ml[wS5Jwf3SqIHnubIljcXSxcomgZZN{[Xl? NF3HS3J,OTByIN88US=> NY\tRmhvTE2VTx?= MXLpcohq[mm2czD0bIUh\3Kxd4To NYLQVlJMOjR7ME[xN|c>
Mel-JD M3e3b2dzd3e2aDDpcohq[mm2b4L5JIF{e2G7 M4rBeJ4yODBizszN NWC5b2E{TE2VTx?= M1TneIlvcGmkaYTzJJRp\SCpcn;3eIg> NIP4UlEzPDlyNkGzOy=>
Mel-RM MojFS5Jwf3SqIHnubIljcXSxcomgZZN{[Xl? MUX+NVAxKM7:TR?= NVy5NI9pTE2VTx?= M1HCdIlvcGmkaYTzJJRp\SCpcn;3eIg> M{PSc|I1QTB4MUO3
Me007 M2jXbmFxd3C2b4Ppd{Bie3OjeR?= MYD+NVAxKM7:TR?= NVO3Z3NoTE2VTx?= NUn4[lZIcW6mdXPld{BieG:ydH;zbZM> M37zcVI1QTB4MUO3
SK-Mel-28 MWfBdI9xfG:|aYOgZZN{[Xl? NXrjTGNQhjFyMDFOwG0> NVXjbWVJTE2VTx?= M4TRcIlv\HWlZYOgZZBweHSxc3nz MXGyOFkxPjF|Nx?=
Mel-RMU MkHzRZBweHSxc3nzJIF{e2G7 MUL+NVAxKM7:TR?= MUnEUXNQ NHnrUVlqdmS3Y3XzJIFxd3C2b4Ppdy=> M3PYZlI1QTB4MUO3
Mel-JD NGf3bHpCeG:ydH;zbZMh[XO|YYm= MVT+NVAxKM7:TR?= NV\EcZpzTE2VTx?= MWLpcoR2[2W|IHHwc5B1d3Orcx?= M{DyOFI1QTB4MUO3
Mel-RM MoPVRZBweHSxc3nzJIF{e2G7 MX7+NVAxKM7:TR?= M2jTTWROW09? MnLrbY5lfWOnczDhdI9xfG:|aYO= MXKyOFkxPjF|Nx?=
Me007 M{LtV2Z2dmO2aX;uJIF{e2G7 MnPCNVAh|ryP MYLEUXNQ M{jJeolv\HWlZYOgZ4VtdCCleXPs[UBienKnc4SgZpkhfXC{ZXf1cIF1cW:wIH;mJJAzOQ>? NHHzVWczPDlyNkGzOy=>
SK-Mel-28 MkTYSpVv[3Srb36gZZN{[Xl? MmPlNVAh|ryP NF;mR5FFVVOR M1LMZ4lv\HWlZYOgZ4VtdCCleXPs[UBienKnc4SgZpkhfXC{ZXf1cIF1cW:wIH;mJJAzOQ>? MWqyOFkxPjF|Nx?=
Mel-RMU MoXiSpVv[3Srb36gZZN{[Xl? M3nVNFExKM7:TR?= NFj2WpVFVVOR MkS5bY5lfWOnczDj[YxtKGO7Y3zlJIFzemW|dDDifUB2eHKnZ4XsZZRqd25ib3[gdFIy MUOyOFkxPjF|Nx?=
Mel-JD NVfLUolYTnWwY4Tpc44h[XO|YYm= NFX6XlIyOCEQvF2= M4HsdmROW09? Mk\KbY5lfWOnczDj[YxtKGO7Y3zlJIFzemW|dDDifUB2eHKnZ4XsZZRqd25ib3[gdFIy NXnKSplZOjR7ME[xN|c>
Mel-RM MlPxSpVv[3Srb36gZZN{[Xl? MV:xNEDPxE1? NIXOXnhFVVOR NEfvVIRqdmS3Y3XzJINmdGxiY4njcIUh[XK{ZYP0JIJ6KHWycnXneYxifGmxbjDv[kBxOjF? MYqyOFkxPjF|Nx?=
Me007 NGfEXoxHfW6ldHnvckBie3OjeR?= M2jXOlExKM7:TR?= MXfEUXNQ MmW4eZBz\We3bHH0[ZMheHKxYYDvdJRwfGmlIHHu[EBk\WyuIHP5Z4xmKGG{cnXzeEBo\W6ncx?= NXP4Wo1ZOjR7ME[xN|c>
SK-Mel-28 NViydpJETnWwY4Tpc44h[XO|YYm= M3\yUlExKM7:TR?= NEHFWWNFVVOR M3HEeJVxemWpdXzheIV{KHC{b3Hwc5B1d3SrYzDhcoQh[2WubDDjfYNt\SCjcoLld5Qh\2WwZYO= NGPVfIwzPDlyNkGzOy=>
Mel-RMU MojWSpVv[3Srb36gZZN{[Xl? MUWxNEDPxE1? NFnUWHRFVVOR MkTSeZBz\We3bHH0[ZMheHKxYYDvdJRwfGmlIHHu[EBk\WyuIHP5Z4xmKGG{cnXzeEBo\W6ncx?= Mn\vNlQ6ODZzM{e=
Mel-JD NHvhfohHfW6ldHnvckBie3OjeR?= MoKwNVAh|ryP M1jFfWROW09? MknLeZBz\We3bHH0[ZMheHKxYYDvdJRwfGmlIHHu[EBk\WyuIHP5Z4xmKGG{cnXzeEBo\W6ncx?= MmfuNlQ6ODZzM{e=
Mel-RM Mo\ZSpVv[3Srb36gZZN{[Xl? MkfvNVAh|ryP Mo\1SG1UVw>? MoKxeZBz\We3bHH0[ZMheHKxYYDvdJRwfGmlIHHu[EBk\WyuIHP5Z4xmKGG{cnXzeEBo\W6ncx?= NWTO[21ROjR7ME[xN|c>

... Click to View More Cell Line Experimental Data

In vivo Administration of I-BET151 at 30 mg/kg/day significantly inhibits tumor growth of murine MLL-AF9 and human MLL-AF4 leukaemia in mice, and provides marked survival benefit. [1]

Protocol

Kinase Assay:

[1]

+ Expand

Fluorescence anisotropy (FP) ligand displacement assay:

All components are dissolved in buffer of composition 50 mM HEPES pH 7.4, 150 mM NaCl and 0.5 mM CHAPS with final concentrations of BRD 2/3/4 75 nM, fluorescent ligand 5 nM. 10 μL of this reaction mixture is added using a micro multidrop to wells containing 100 nL of various concentrations of I-BET151 or DMSO vehicle (1% final) in Greiner 384 well Black low volume microtitre plate and equilibrated in the dark for 60 minutes at room temperature. Fluorescence anisotropy is read in Envision (lex = 485 nm, lEM = 530 nm; Dichroic = 505 nM).
Cell Research:

[1]

+ Expand
  • Cell lines: MV4;11, MOLM13, NOMO1, RS4;11, HEL, HL60 and K562
  • Concentrations: Dissolved in DMSO, final concentrations ~100 μM
  • Incubation Time: 24, or 72 hours
  • Method:

    Cells are exposed to various concentrations of I-BET151 for 24 or 72 hours in 384-well or 96-well plates. For cell growth inhibition assays, plates are added with CellTiter-Glo reagent using a volume equivalent to the cell culture volume in the wells, shaken for approximately 2 minutes and chemiluminescent signal is read on the Analyst GT or EnVision Plate Reader. For cell proliferation assays, CellTiter-Aqueous One is added to each well and plates are incubated for 4 hours at 37 °C. Absorbance is read at 490 nm on a SpectraMax Gemini reader


    (Only for Reference)
Animal Research:

[1]

+ Expand
  • Animal Models: NOD-SCID mice injected intravenously with MV4;11 cells, and C57BL/6 mice injected intravenously with MLL-AF9 cells
  • Formulation: Dissolved in normal saline containing 5% (v/v) DMSO and 10% (w/v) Kleptose HPB
  • Dosages: ~30 mg/kg/day
  • Administration: Intraperitoneal injection
    (Only for Reference)

Solubility (25°C)

In vitro Ethanol 27 mg/mL (64.99 mM)
DMSO Insoluble
Water Insoluble

* Please note that Selleck tests the solubility of all compounds in-house, and the actual solubility may differ slightly from published values. This is normal and is due to slight batch-to-batch variations.

Chemical Information

Molecular Weight 415.44
Formula

C23H21N5O3

CAS No. 1300031-49-5
Storage powder
Synonyms N/A

Bio Calculators

Molarity Calculator

Molarity Calculator

Calculate the mass, volume or concentration required for a solution. The Selleck molarity calculator is based on the following equation:

Mass (g) = Concentration (mol/L) × Volume (L) × Molecular Weight (g/mol)

  • Mass
    Concentration
    Volume
    Molecular Weight

*When preparing stock solutions, please always use the batch-specific molecular weight of the product found on the via label and MSDS / COA (available on product pages).

Dilution Calculator

Dilution Calculator

Calculate the dilution required to prepare a stock solution. The Selleck dilution calculator is based on the following equation:

Concentration (start) x Volume (start) = Concentration (final) x Volume (final)

This equation is commonly abbreviated as: C1V1 = C2V2 ( Input Output )

  • C1
    V1
    C2
    V2

* When preparing stock solutions always use the batch-specific molecular weight of the product found on the vial label and MSDS / COA (available online).

The Serial Dilution Calculator Equation

  • Serial Dilutions

  • Computed Result

  • C1=C0/X C1: LOG(C1):
    C2=C1/X C2: LOG(C2):
    C3=C2/X C3: LOG(C3):
    C4=C3/X C4: LOG(C4):
    C5=C4/X C5: LOG(C5):
    C6=C5/X C6: LOG(C6):
    C7=C6/X C7: LOG(C7):
    C8=C7/X C8: LOG(C8):
Molecular Weight Calculator

Molecular Weight Calculator

Enter the chemical formula of a compound to calculate its molar mass and elemental composition:

Total Molecular Weight: g/mol

Tip: Chemical formula is case sensitive. C10H16N2O2 c10h16n2o2

Instructions to calculate molar mass (molecular weight) of a chemical compound:

To calculate molar mass of a chemical compound, please enter its chemical formula and click 'Calculate'.

Definitions of molecular mass, molecular weight, molar mass and molar weight:

Molecular mass (molecular weight) is the mass of one molecule of a substance and is expressed in the unified atomic mass units (u). (1 u is equal to 1/12 the mass of one atom of carbon-12)
Molar mass (molar weight) is the mass of one mole of a substance and is expressed in g/mol.

Molarity Calculator

Mass Concentration Volume Molecular Weight

Tech Support

Answers to questions you may have can be found in the inhibitor handling instructions. Topics include how to prepare stock solutions, how to store inhibitors, and issues that need special attention for cell-based assays and animal experiments.

Handling Instructions

Tel: +1-832-582-8158 Ext:3

If you have any other enquiries, please leave a message.

  • * Indicates a Required Field

Epigenetic Reader Domain Signaling Pathway Map

Epigenetic Reader Domain Inhibitors with Unique Features

Tags: buy I-BET151 (GSK1210151A) | I-BET151 (GSK1210151A) supplier | purchase I-BET151 (GSK1210151A) | I-BET151 (GSK1210151A) cost | I-BET151 (GSK1210151A) manufacturer | order I-BET151 (GSK1210151A) | I-BET151 (GSK1210151A) distributor
×
Cell Lines Assay Type Concentration Incubation Time Formulation Activity Description PMID